Viewing Study NCT05038735


Ignite Creation Date: 2025-12-24 @ 10:34 PM
Ignite Modification Date: 2026-01-01 @ 5:23 AM
Study NCT ID: NCT05038735
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-03
First Post: 2021-09-01
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
Sponsor: Novartis Pharmaceuticals
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module